Compare

Innovage/$INNV

1D1W1M3M6MYTD1Y5YMAX

About Innovage

InnovAge Holding Corp is a healthcare delivery platform comprising multiple participants focused on providing all-inclusive, capitated care to high-cost seniors, many of whom are dual-eligible. Its programs are designed to address two of the pressing challenges facing the U.S. healthcare industry: rising costs and poor outcomes. The purpose of the participant-centered care delivery approach is to improve the quality of care participants receive, while keeping them in their homes for as long as possible and reducing the overutilization of high-cost care settings, such as hospitals and nursing homes. It manages its business as one reportable segment, PACE.
Ticker
$INNV
Sector
Health
Primary listing
NASDAQ
Employees
2,500
Headquarters
Denver, United States
Website
www.innovage.com

Innovage Metrics

BasicAdvanced
$1.3B
-
-$0.02
0.39
-

What the Analysts think about Innovage

Analyst ratings (Buy, Hold, Sell) for Innovage stock.
Analyst projections of the future price of Innovage stock.

Bulls say / Bears say

Fiscal 2026 showed a sharp operating recovery: revenue rose 15.9%, adjusted EBITDA climbed to $94.6 million from $34.5 million, and centre-level contribution margin expanded to 23% from 18%. (InnovAge)
Management forecasts fiscal 2027 revenue of $1.05–$1.085 billion and adjusted EBITDA of $105–$115 million, implying further growth even as it expects a more moderate rate environment. This gives the company a near-term earnings target to build on its improved margins. (InnovAge, Investing.com)
PACE remains a substantially underpenetrated market: InnovAge estimates about 2.3 million people are eligible, while roughly 95,000 were enrolled in PACE as of June 2026. As the largest US PACE provider, with 8,230 participants across 20 centres, InnovAge has room to grow within and beyond its existing footprint. (SEC)
Reimbursement pressure could squeeze fiscal 2027 margins. California and Colorado account for about 70% of census, state rate-setting remains unsettled, and the company anticipates a Colorado Medicaid rate decrease. (SEC, InnovAge)
Regulatory and compliance issues could constrain growth: the company is still working through a corrective action plan following a California review, and state attestations for planned centres were suspended. It withdrew its Downey application and says progress on Bakersfield depends on successful remediation. (SEC)
The strong adjusted EBITDA headline has not yet translated into robust GAAP earnings: InnovAge reported a $0.7 million net loss for fiscal 2026 and only $2.6 million of operating income on nearly $990 million of revenue. That leaves limited room for further cost shocks or weaker reimbursement. (InnovAge, SEC)
Data summarised monthly by Lightyear AI. Last updated on 20 Oct 2026.

Innovage Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

Innovage Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

Innovage News

AllArticlesVideos

InnovAge Q4 Earnings Call Highlights

MarketBeat2 months ago

Funds containing Innovage

Funds
Fund name
Fund size
$INNV weighting
SPDR Russell 2000 US Small Cap£R2SC
$5.3B0.01%
SPDR Russell 2000 US Small Cap€R2US
$5.3B0.01%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.